Loading...
Market
What stage of clinical trials will the new Alzheimer's drug reach by the end of 2025?
2
Resolution / Starting Odds
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Official announcements from the drug developers or regulatory bodies
Story
New Drug Completes Preclinical Stage, Offers Hope for Rapid Alzheimer's Diagnosis
Oct 18, 2024, 09:18 AM
A new drug developed by specialists from Russian Peter the Great St. Petersburg Polytechnic University aims to protect Alzheimer's patients from memory loss. The drug's main substance, piperazine, is designed to target the brain effectively and has completed the preclinical stage. This development comes amid ongoing efforts to improve dementia diagnosis and treatment. Currently, it takes more than seven years on average to diagnose dementia, but new tests offer hope for rapid diagnosis. Experts are also exploring the potential of 'repurposed' drugs to limit the progression of dementia.
View original story
Similar markets
Statistically significant improvement • 25%
No significant difference • 25%
Worse outcomes • 25%
Trial terminated early • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Yes • 50%
No • 50%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Successful with minimal efficacy • 25%
Unsuccessful • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
Trial discontinued • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Approved • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Not in Top 5 • 25%
Preclinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 or beyond • 25%